LSV Asset Management’s Sciclone Pharmaceuticals SCLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SCLN
LSV Asset Management's SCLN Position: Q2 2017 in Review
LSV Asset Management sold out of Sciclone Pharmaceuticals (SCLN) in Q2 2017, closing a stake of 97,964 shares — an estimated $960K sold.
LSV Asset Management first reported a position in SCLN in Q2 2013 and held it in 16 quarters. The position peaked at $16.2M in Q3 2014. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.
- LSV Asset Management reported no remaining Sciclone Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
- LSV Asset Management sold 97,964 Sciclone Pharmaceuticals shares in Q2 2017, an estimated $960K.
- LSV Asset Management first reported a position in Sciclone Pharmaceuticals in Q2 2013 and held it in 16 quarters.
- LSV Asset Management's Sciclone Pharmaceuticals position peaked at $16.2M in Q3 2014.
- 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals as of Q2 2017.
Based on LSV Asset Management's 13F filing for Q2 2017, filed 9 Aug 2017.